Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Stiefel Acquires Topical Agent From Welichem | Contract Pharma

What are you searching for?

Sign in
Breaking News

Stiefel Acquires Topical Agent From Welichem

Welichem will receive an initial $34 million payment

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Stiefel, a GSK company, has entered into an agreement with Welichem Biotech to acquire exclusive development and commercialization rights to the anti-inflammatory agent, WBI-1001, in all territories outside of China, Taiwan, Macao and Hong Kong. WBI-1001 is currently in Phase II development for the treatment of psoriasis and atopic dermatitis. The transaction is subject to approval by Welichem shareholders.

Welichem will receive an initial payment of $34 million and is eligible to receive additional payments based on clinical development milestones. Stiefel also has an option to acquire further exclusive rights to develop and commercialize WBI-1001 in China, Taiwan, Macao and Hong Kong, collectively. Upon satisfaction of certain conditions, Welichem will receive an additional payment of $14.6 million.

“I’m delighted to build upon Stiefel’s clinical pipeline of novel dermatology assets with the acquisition of WBI-1001,” said Barbara White, senior vice president and head of R&D, Stiefel. “We have a strong commitment to patients with skin conditions and are excited to undertake development of this innovative agent.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics